AKT is a protein in the phosphatidylinositol-3 kinase (PI3K) pathway and associated with diverse pro-tumoral responses. Activation of the human telomere reverse transcriptase (hTERT) is one of AKT's tumorigenic effects. In this study, the significance of AKT phosphorylation and hTERT on prognosis of gastric cancer were examined. AKT activation by epidermal growth factor increased hTERT expression and telomerase activity. In contrast, AKT inactivation by inhibitors and knockdown decreased hTERT expression and telomerase activity in MKN28 gastric cancer cells. In 40 gastric cancer tissues, significant correlations were found among the levels of phosphorylated AKT (pAKT), hTERT expression, and telomer length. The pAKT levels or the levels of pAKT/hTERT were not associated with clinicopathological parameters, including stage and nodal metastasis. However, survival rates of the pAKT-high patients or the pAKT-high and hTERT-high patients were significantly poorer than those in other patients. These findings suggest that AKT and hTERT are good molecular targets for the treatment of gastric cancer.

Keywords:
AKT, TERT, Telomerase, Prognosis
1.
Blackburn EH: Switching and signaling at the telomere. Cell 2001;106:661-673.
2.
Lingner J, Cooper JP, Cech TR: Telomerase and DNA end replication: No longer a lagging strand problem? Science 1995;269:1533-1534.
3.
Stewart SA, Weinberg RA: Telomeres: Cancer to human aging. Annu Rev Cell Dev Biol 2006;22:531-557.
4.
Autexier C, Lue NF: The structure and function of telomerase reverse transcriptase. Annu Rev Biochem 2006;75:493-517.
5.
Kuniyasu H, Kitadai Y, Mieno H, Yasui W: Helicobactor pylori infection is closely associated with telomere reduction in gastric mucosa. Oncology 2003;65:275-282.
6.
Sukawa Y, Yamamoto H, Nosho K, Kunimoto H, Suzuki H, Adachi Y, Nakazawa M, Nobuoka T, Kawayama M, Mikami M, Matsuno T, Hasegawa T, Hirata K, Imai K, Shinomura Y: Alterations in the human epidermal growth factor receptor 2-phosphatidylinositol 3-kinase-v-AKT pathway in gastric cancer. World J Gastroenterol 2012;18:6577-6586.
7.
Berg M, Soreide K: EGFR and downstream genetic alterations in KRAS/BRAF and PI3K/AKT pathways in colorectal cancer: Implications for targeted therapy. Discov Med 2012;14:207-214.
8.
Ng L, Poon RT, Pang R: Biomarkers for predicting future metastasis of human gastrointestinal tumors. Cell Mol Life Sci 2013;in press.
9.
Cheung M, Testa JR: Diverse mechanisms of AKT pathway activation in human malignancy. Curr Cancer Drug Targets 2013;13:234-244.
10.
Downward J: PI 3-kinase, AKT and cell survival. Semin Cell Dev Biol 2004;15:177-182.
11.
Radisavljevic Z: AKT as locus of cancer angiogenic robustness and fragility. J Cell Physiol 2013;228:21-24.
12.
Xu M, Mo YY: The AKT-associated microRNAs. Cell Mol Life Sci 2012;69:3601-3612.
13.
Li H, Zhao L, Yang Z, Funder JW, Liu JP: Telomerase is controlled by protein kinase Cα in human breast cancer cells. J Biol Chem 1998;273:33436-33442.
14.
Kang SS, Kwon T, Kwon DY, Do SI: Akt protein kinase enhances human telomerase activity through phosphorylation of telomerase reverse transcriptase subunit. J Biol Chem 1999;274:13085-13090.
15.
Kim JH, Park SM, Kang MR, Oh SY, Lee TH, Muller MT, Chung IK: Ubiquitin ligase MKRN1 modulates telomere length homeostasis through a proteolysis of hTERT. Genes Dev 2005;19:776-781.
16.
Kuniyasu H, Oue N, Wakikawa A, Shigeishi H, Matsutani N, Kuraoka K, Ito R, Yokozaki H, Yasui W: Expression of receptors for advanced glycation end-products (RAGE) is closely associated with the invasive and metastatic activity of gastric cancer. J Pathol 2002;196:163-170.
17.
Populo H, Lopes JM, Soares P: The mTOR signalling pathway in human cancer. Int J Mol Sci 2012;13:1886-1918.
18.
Karamitopoulou E: Tumor budding cells, cancer stem cells and epithelial-mesenchymal transition-type cells in pancreatic cancer. Front Oncol 2012;2:209.
19.
Liu Z, Li Q, Li K, Chen L, Li W, Hou M, Liu T, Yang J, Lindvall C, Bjorkholm M, Jia J, Xu D: Telomerase reverse transcriptase promotes epithelial-mesenchymal transition and stem cell-like traits in cancer cells. Oncogene 2012;advance online publication.
20.
Fidler IJ: The pathogenesis of cancer metastasis: The ‘seed and soil' hypothesis revisited. 2003;3:453-458.
21.
Claesson-Welsh L, Welsh M: VEGFA and tumour angiogenesis. J Intern Med 2013;273:114-127.
22.
Karar J, Maity A: PI3K/AKT/mTOR pathway in angiogenesis. Front Mol Neurosci 2011;4:51.
23.
Japanese Gastric Cancer Association: Japanese classification of gastric carcinoma: 3rd English edition. Gastric Cancer 2011;14:101-112.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.